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Abstract
Background: Chronic lymphocytic leukemia (CLL) is the most common hematological malignancy in western
countries, characterized by a heterogeneous clinical course. Although genetic studies have identified chromosomal
aberrations or specific mutations, epigenetic changes have been poorly characterized in CLL.
Methods: We assessed ten-eleven translocations (TET) 1, 2, and 3, isocitrate dehydrogenase (IDH) 1, and 2
messenger RNA (mRNA) expression using real-time PCR on purified leukemic B cells from 214 CLL patients (median
follow-up = 75 months, range 1–380), normal peripheral blood B cells (n = 20), and umbilical cord blood B cells
(n = 21). The microenvironment influence was assessed after 24 h co-culture of CLL cells with bone marrow
mesenchymal stromal cells (BMSC). Finally, 5-hydroxymethylcytosine level (%5-hmC) was assessed by ELISA in CLL
cells alone or with microenvironment stimuli.
Results: TET 1 and 3 and IDH2 were decreased in CLL cells compared with healthy B cells (P = 0.0221, 0.0013,
<0.0001, respectively), while IDH1 was overexpressed (P = 0.0037). TET2 and IDH1 were significantly correlated with
treatment-free survival (TFS); patients with high TET2/IDH1 expression had a higher median TFS (111 months) than
patients with low expression (78 months, P = 0.0071/0.0123). Moreover, TET1 expression decreased (P = 0.0371), while
TET3 and IDH2 expression increased (P = 0.0273/0.0039) in co-cultures. However, %5-hmC was not correlated with
clinical data and was unchanged following microenvironment stimuli.
Conclusions: Despite a slight deregulation in CLL cells compared with normal B cells, we identified a significant
association between TET/IDH gene expression and prognosis, suggesting that epigenetic changes could potentially be
associated with disease progression. Moreover, despite an identical %5-hmC, TET gene expression was influenced by
contact with BMSC confirming the crucial role of the microenvironment in CLL pathogenesis.
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Background
Chronic lymphocytic leukemia (CLL) is the most com-
mon hematological malignancy in the west and is char-
acterized by a heterogeneous clinical course [1]; some
patients will live several decades without any symptoms,
while others will rapidly require a treatment and will have
a decreased overall survival (OS). Clinical and molecular
factors, such as Binet stage, lymphocyte doubling time
(LDT), mutational status of the immunoglobulin heavy-
chain variable-region (IgHV), zeta-chain-associated pro-
tein kinase 70 (ZAP70), lipoprotein lipase (LPL) or CD38
expression, and serum levels of soluble CD23 (sCD23)
and beta-2-microglobulin (B2M), can be used to classify
patients into different prognostic subgroups [2]. Moreover,
increasing evidence suggests a role for the microenviron-
ment in CLL pathogenesis. Our group previously demon-
strated that bone marrow mesenchymal stromal cells
(BMSC) protect CLL but not normal B cells from apop-
tosis through direct contact [3].
While genetic lesions, such as chromosomal aberrations
[4] or specific mutations, [5–8] are involved in CLL phys-
iopathology, in recent years, growing evidence has sug-
gested that epigenetic characteristics are key factors in
leukemic processes. Recent studies have investigated epi-
genetic features and demonstrated the importance of
DNA methylation [9] or histone post-translational modifi-
cations in prognosis, oncogene regulation, or therapeutic
targeting [10–12]. We demonstrated in previous papers
that histone deacetylase (HDAC) mRNA expression was
associated with poor (HDAC7, HDAC10, and SIRT5) or
good prognosis (HDAC6, SIRT3, and SIRT6) [13] in CLL
patients. Moreover, global HDAC enzymatic activity is a
strong predicator of poor prognosis in CLL which can re-
fine well-known prognostic factors [14].
In 2009, Tahiliani and colleagues discovered 5-
hydroxymethylcytosine (5-hmC) as the sixth base of the
DNA in mammalian cells [15]. Ten-eleven translocation
proteins (TET) are the dioxygenases responsible for the
oxidation of 5-methylcytosine (5-mC) to form 5-hmC.
There are three known TET isoenzymes (TET1, 2, and 3),
and they require oxygen, Fe(II), and 2-oxoglutarate for
their activity. This last cofactor is produced in the Krebs
cycle by the isocitrate dehydrogenases (IDH) 1 and 2.
Other subsequent studies suggested that the 5-hmC
marker could be a step in the demethylation process
[16–21] and/or a pattern allowing specific enzymes to
bind hydroxymethylated regions of the genome [22–26].
Hydroxymethylation enzyme defects have previously
been associated with hematological malignancies; mu-
tations in TET2 were found in acute myeloid
leukemia (AML) or chronic myelomonocytic leukemia
(CMML) and induced loss of hydroxymethylation and
were linked with poor prognosis [27–30]. However,
reports on TET2 mutations in B cell neoplasms are
rare [31], and little is known about DNA hydroxy-
methylation in CLL.
In the present study, we measured the mRNA expression
of TET1, 2, and 3 and IDH1 and 2 by quantitative real-time
PCR (qPCR) in highly purified CD19+ B cells from a large
cohort of CLL patients (n = 214) and correlated these data
with clinical outcome. We also investigated the potential
association between the global DNA 5-hmC rate and
microenvironment stimuli, especially BMSC.
Methods
Patients and samples
This study was approved by the Bordet Institute Ethics
Committee and conducted according to the principles
expressed in the Declaration of Helsinki. All samples
were collected at the time of diagnosis before any treat-
ment, and after, written informed consent was obtained
from 214 CLL patients who presented with a typical
CD19+CD5+CD23+ phenotype and a Catovsky score of
4 or 5/5. Treatment-free survival (TFS) and OS were cal-
culated from the time of diagnosis until the date of first
treatment and the date of death, respectively. All deaths
were CLL-related. Control samples were obtained from
the peripheral blood of 20 age-matched healthy volun-
teers (PBHV) (mean 69 years old, range 54–90) after
written informed consent was obtained and from 21 um-
bilical cord blood (UCB) samples after full-term delivery
and written informed consent of the mothers was ob-
tained. Leukemic B cells were isolated from mono-
nuclear cells with magnetic beads targeting CD19+
phenotype (MidiMACS, Miltenyi Biotec). Briefly, pellet
of 10 million mononuclear cells were resuspended in
80 μl of PBS-05% BSA and 20 μl of CD19 microbeads.
After 15 min of incubation at 4 °C and washing, cell sus-
pension was applied onto a column placed in a magnetic
field. Three washes were performed to discard unlabeled
cells and then the column was removed to the separator
and placed on a collector tube where magnetically la-
beled cells were flushed out. For experiments which re-
quire culture, cells were negatively isolated by an
indirect magnetic labeling system (B-CLL Cell Isolation
Kit from MidiMACS, Miltenyi Biotec) to avail any cell
activation or apoptosis. The isolation process is per-
formed in two steps: a first labeling with a cocktail of
biotin-conjugated monoclonal anti-human antibodies
and then, after incubation, an adding of anti-biotin
microbeads. CD19+ cells are directly collected during
the elution of the column.
BMSC isolation and conditioned medium preparation
BMSC were harvested from the sternum or iliac crest of
healthy volunteers and were isolated by the classical adhe-
sion method, as previously described [32]. Conditioned
media were prepared from 24 h cultures of BMSC alone
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or CLL B cells + BMSC with and without contact (sepa-
rated by a 0.4-μm pore-size filter). Cultures of CLL B cells
with BMSCs or different conditioned media were per-
formed for 24 h.
Assessment of classic prognostic factors
ZAP70 and LPL were measured by qPCR as previously
described [33]. CD38 expression was assessed by flow
cytometry, sCD23 and B2M were measured by ELISA,
and IgHV gene mutational analysis was performed using
the IGH Somatic Hypermutation Assay v2.0 (Invivo-
scribe–Ref. 5-101-0031). LDT was assessed according to
Montserrat et al. [34]. Classical cytogenetics by standard
karyotype analysis and additional interphase FISH were
performed to screen for the most common aberrations
using the Chromoprobe Multiprobe® CLL System (Cyto-
cell, Amplitech–Ref. PMP 018/017/016/020). Patients
were then classified according to the recommendations
of Döhner and Cuneo et al. [4, 35]. Additional details
can be found in Additional file 1: Text 1. All of these
factors, except B2M for OS, were shown to be significant
predictors of TFS and OS, indicating that our cohort is
representative of a CLL population (Additional file 1:
Figure S1 and Table S1).
RNA and DNA extraction and expression quantification
Total RNA was extracted from purified CD19+ cells in a
single step using TriPure Isolation Reagent (Roche Life
Science–Ref. 11 667 165 001). Complementary DNA
(cDNA) was generated from 500 ng of RNA using qScript
cDNA SuperMix (Quanta Biosciences–Ref. 95048-100)
according to the manufacturer’s protocol. TET1, 2, and 3
and IDH1 and 2 mRNA expression was quantified by
real-time PCR using SYBR Green technology (Applied
Biosystems–Ref. 4367659). Gene expression was normal-
ized to the cyclophilin A (PPIA) gene as an endogenous
control as previously described [13] and calibrated by
subtracting 10 (chosen arbitrarily) from the ΔCt. The
comparative ΔΔCt method was then used for data ana-
lysis, and the fold changes were subsequently calculated
(fold change = 2−ΔΔCt). All primer sequences are available
in the Additional file 1: Text 1 (Life Technologies).
Genomic DNA (gDNA) was extracted from purified
CD19+ cells with a QIAamp DNA Blood Mini Kit
(Qiagen–Ref. 51104).
Assessment of 5-hmC levels
We measured the 5-hydroxymethylcytosine percentage
(%5-hmC) using a “Quest 5-hmC DNA ELISA Kit”
(Zymo Research–Ref. D5425). Briefly, 150 ng of dena-
tured DNA was added to wells coated with 200 ng of
anti-5-hydroxymethylcytosine polyclonal antibodies. The
signal was detected at 405 nm after washing and adding
the anti-DNA HRP (horseradish peroxidase) antibodies.
Optic density was converted to %5-hmC using a standard
curve based on five controls (with values of 0, 0.03, 0.12,
0.23, and 0.55%) provided in the kit. To quantify %5-hmC,
we normalized the ELISA results with data obtained from
the quantification of three genes (glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH), actin, and PPIA) in each
gDNA sample. Because these three endogenous controls
produced similar results (indicating that an equivalent
DNA quantity was loaded), we only used GAPDH and
expressed the results as %5-hmC/GAPDH.
Statistical analysis
The patients were stratified according to low and high
TET or IDH expression with a cut-off value set by recur-
sive partitioning maximizing the concordance with TFS
as previously described for other prognostic factors [14].
All median comparisons were performed with a Mann–
Whitney test or a Wilcoxon test for paired comparisons.
TFS and OS analyses were performed with the Kaplan–
Meier curves, and differences between groups in terms
of prognosis were assessed with a log-rank test. All tests
were two-sided. Differences were considered statistically
significant at P < 0.05. All analyses were performed using




The median age of the population was 63 years (range
34–86). The median treatment-free survival (TFS) was
88.07 months (range 0.33–251.43), and the median OS
was 241.87 months (range 0.40–380.20). The median
follow-up was 74.53 months (range 0.40–380.20). In this
population, prognostic factors, such as IgHV mutational
status, ZAP70, CD38, Binet stage, sCD23, B2M, LDT,
and cytogenetic profile (cytog. profile), were significantly
correlated with TFS and OS (P < 0.05), except B2M for
OS (Additional file 1: Figure S1). Complete prognostic
data were not available for all patients due to a lack of
biological material. ZAP70, LPL expression, and CD38 ex-
pression and clinical data were available for all 214 patients
included in this study. Incomplete data were available for
IgHV mutational status (97.20%), LDT (84.11%), B2M
(87.38%), sCD23 (81.78%), and cytog. profile (74.30%). All
prognostic factors (except B2M for OS) were shown to be
associated with prognosis, indicating that these 214 CLL
patients comprise a classical CLL cohort.
TET1 and 3 and IDH1 and 2 are deregulated in CLL
TET1, 2, and 3 and IDH1 and IDH2 were measured in
CD19+ CLL samples (mean purity 99.2%, range 97.5–
99.9) and compared with the normal CD19+ cells. We
used two types of normal counterparts: CD19+ purified
B cells from the peripheral blood of healthy volunteers
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(mean purity 97.9%, range 95.7–100) and CD19+ purified B
cells from umbilical cord blood (mean purity 98.6, range
96.4–99.5), which are CD5+ (mean 88.6% ±1.5, range 80.9–
97.6), similar to CLL B cells (mean 98.0% ±0.2, range 91–
100) as discussed previously. Compared with B cells from
the PBHV, we observed that leukemic cells had decreased
expression of TET1 and 3 and IDH2 (P = 0.0221, 0.0013,
<0.0001, respectively) but overexpressed IDH1 (P =
0.0037). Compared with B cells from UCB, TET2, TET3,
and IDH2 were underexpressed in leukemic cells (P =
0.0016, <0.0001, <0.0001, respectively) (Fig. 1). ΔCt repre-
sentation of these data is also provided in Additional file
1: Figure S2. These results indicated that hydroxymethyla-
tion enzyme expression is deregulated in CLL.
High TET2 or IDH1 expression is associated with good
prognosis in terms of TFS
The patients were then stratified for each studied en-
zyme in high and low expression groups with a cut-off
value set by recursive partitioning maximizing the con-
cordance with TFS. The cut-offs of the fold changes
values for TET1, TET2, TET3, IDH1 and IDH2 were, re-
spectively, 2.403, 22.317, 7.964, 4.268, and 15.270. TET2
and IDH1 were both significantly correlated with TFS (P
= 0.0059 and 0.0123, respectively). Patients with high
mRNA expression of TET2 or IDH1 had a median TFS
of 111 months, while patients with low expression had a
median TFS of 78 months. However, there were no sig-
nificant correlations with OS (Fig. 2). TET and IDH gene
Fig. 1 TET and IDH mRNA expression in CLL and control samples. Fold changes in mRNA expression of a TET1, b TET2, c TET3, d IDH1, and e
IDH2 in CD19 purified cells from 214 CLL, 20 peripheral blood of healthy patients (PBHV) and 21 umbilical cord blood (UCB) samples are
displayed with median (red). Statistical differences are indicated in relation to CLL and were assessed using the Mann–Whitney
non-parametric test
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Fig. 2 Prognostic power of TET and IDH gene mRNA expression. Fold changes in enzyme mRNA expression were measured by qPCR, and
cut-offs were set by recursive partitioning. TFS and OS Kaplan–Meier curves are displayed for a, b TET1, c, d TET2, e, f TET3, g, h IDH1 and, i, j
IDH2. Statistical differences between the curves were calculated using the log-rank test
Van Damme et al. Clinical Epigenetics  (2016) 8:132 Page 5 of 11
expression was also compared between the groups based
on well-known prognostic factors (IgHV mutational sta-
tus, ZAP70, CD38, Binet stage, sCD23, B2M, LDT, and
cytogenetic profile). No obvious and important signifi-
cant differences were observed (Additional file 1: Tables
S2 and S3).
TET1, TE3, and IDH2 expression is influenced by
microenvironment stimuli but global %5-hmC is
unchanged
Because microenvironment stimuli are known to influ-
ence the cellular physiology of CLL B cells, we measured
TET and IDH expression in leukemic cells before and
after contact with BMSC (Fig. 3a–e). We observed a
downregulation of TET1 (10.31 vs 8.18, P = 0.0371) and
an upregulation of TET3 (26.73 vs 36.40, P = 0.0273)
and IDH2 (48.78 vs 84.32, P = 0.0039). However, these
modifications in mRNA expression were not associated
with an alteration in global %5mC (Fig. 3f ), as it was
similar in both conditions (0.0900 vs 0.0990, P = 0.4768).
To ensure that BMSC co-culturing did not contaminate
the subsequent DNA extraction, we cultured CLL B cells
in the conditioned medium of BMSC alone or BMSC +
CLL B cells (with and without contact). None of these
conditions showed significant differences in terms of %5-
hmC as shown in Fig. 4.
%5-hmC has no prognostic significance in CLL
We performed a comparison of %5-hmC between prog-
nostic subgroups based on classical prognostic factors
(ZAP70, LPL, and CD38), but we did not observed any
significant correlations (P = 0.3837, 0.5467, and 0.8671,
Fig. 3 CLL B cells and BMSC co-cultures impact on TET/IDH mRNA expression and %5-hmC. Fold changes in enzyme mRNA expression of a TET1,
b TET2, c TET3, d IDH1, and e IDH2 were plotted for ten CLL patients for samples cultured alone or with BMSC. f The %5-hmC was measured by
ELISA in nine CLL B cell samples cultured alone and after contact with BMSC. Significance was assessed using the Wilcoxon signed rank test
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respectively; Fig. 5a–c). A log-rank test was also per-
formed following Kaplan–Meier analysis of patients dis-
playing low %5-hmC (n = 15) vs high %5-hmC (n = 15).
Using the median as the positive threshold, we did not
observe a statistical difference (median TFS of 84 vs
49.57 months, respectively, P = 0.7934; Fig. 5d). Other
thresholds (based on recursive partitioning or ROC
curves maximizing the concordance with the mutational
status [14]) gave similar results. OS analysis was not per-
formed due to the absence of deaths among the patients
during the study. Similar results were obtained if we
normalized %5-hmC to actin or PPIA (peptidyl prolyl
isomerase A or cyclophilin A).
Mutation in TET/IDH genes are rare and non-recurrent in CLL
In order to investigate the mutational profile of TET and
IDH genes, we used publically available whole exome
and RNAseq data previously published by Quesada et al.
[36] and Ferreira et al. [37]. Within the CLL-ES project
(accessible on https://dcc.icgc.org/projects/CLLE-ES), sim-
ple somatic mutations were analyzed for a total of 218 pa-
tients. Six patients (2.8%) presented a mutation for TET1,
5 (2.3%) for TET2, 7 (3.2%) for TET3, 5 (2.3%) for IDH1
and 2 (0.9%) for IDH2 for a total of 25 patients with 27
mutations (Table 1). However, only 3 patients (1.4%) pre-
sented a missense mutation respectively in TET1, TET2,
and TET3 genes. All the other mutations in these five
genes were found in intron, UTR (untranslated region),
downstream or upstream the gene indicating that mu-
tations in TET/IDH genes are rare and non-recurrent
events compared to what has been observed in other
hematological malignancies [27–30].
Discussion
In the present paper, we performed a comprehensive
and complete expression profile of the known proteins
involved in DNA hydroxymethylation. To our know-
ledge, it is the first time that such a study has been per-
formed on a large cohort of CLL patients. In 2013,
Hernandez-Sanchez and colleagues observed that TET2
was overexpressed in CLL cells compared with cells
from healthy donors [38]. The normal counterpart of
CLL cells is not clearly defined in the literature and re-
mains controversial [39]. We therefore decided to use
two different controls of normal B cells: first, the periph-
eral normal B cell from healthy donors since they repre-
sent intuitively the normal counterpart in the healthy
donors; second, the B cells from the umbilical cord
blood since they express the CD5 similarly to CLL [40]
and because Saunders et al. demonstrated that they dis-
play a similar proteic profile to CLL [41]. In our results,
TET2 decreased in CLL cells compared with normal B
cells from UCB, but the expression did not differ from
that in the PBHV. These discrepancies could be ex-
plained by at least three reasons: our cohort was larger
than the one used in the previous study (214 vs 23) as
well as the control group of PBHV (20 vs 5); the qPCR
control in the previous study was GAPDH, while we
used PPIA, which is more stable in CLL; and finally,
based on the reverse TET2 primer (the forward has been
mistaken for the GAPDH reverse primer), their ampli-
con was in the 3' region (nucleotide 8941 to 8960), while
ours was further upstream (nucleotide 4367 to 4389)
which is a region less sensible to RNA degradation.
Fig. 4 Normalized 5-hmC levels in CLL B cells cultured alone in RPMI
or with conditioned medium (CM). The different conditioned media
were obtained from supernatants of 24 h cultures of a BMSC, b CLL
B cells + BMSC with contact, and c CLL B cells + BMSC without
contact (separated by a 0.4-μm pore-size filter). Statistical differences
were assessed using the paired Wilcoxon non-parametric test
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In terms of prognosis, we observed that TET2 and
IDH1 were associated with TFS, while the other investi-
gated genes were not; patients expressing a high level of
these enzymes had a longer TFS than the low expression
group. TET2 is a major factor in hematopoiesis, and sev-
eral hematological malignancies, such as myelodysplastic
syndrome [42], acute myeloid leukemia [43], or chronic
myelomonocytic leukemia [44], have been linked to TET2
mutations. IDH1, meanwhile, is a cytosolic enzyme, and
the mutated version produces 2-hydroxyglutarate, a trun-
cated form of 2-oxoglutarate that impairs the function of
enzymes such as TET [45]. Mutations of TET2 are rare in
lymphoid malignancies compared in myeloid malignan-
cies, and based on previous studies, we confirmed in the
present work that no relevant mutations in TET or IDH
enzymes has been found in CLL cells. However, few muta-
tions of TET2 have been observed in other B cell neo-
plasms and more in T cell neoplasms [46, 47]. Several
studies have also reported a skew toward the myeloid
lineage when the TET2 gene is altered [48, 49].
DNA hydroxymethylation, TET enzyme expression,
and prognosis have been investigated in other cancers.
In acute myeloid leukemia, %5-hmC varied among pa-
tients but was correlated with poor OS [50]. In another
study, the hypomethylation agent decitabine was used to
treat elderly AML patients and increased %5-hmC [51].
TET2 was decreased in cervical squamous cell carcin-
oma along with %5-hmC, and low levels in patients were
shown to be associated with a poor prognosis [52]. In
contrast to our results, another team observed that high
expression of IDH1 is associated with shorter overall sur-
vival in cytogenetically normal acute myeloid leukemia
[53]. In epithelial ovarian cancer, TET2 and %5-hmC de-
creased compared with normal controls, and this low ex-
pression was associated with poor overall survival of the
patients [54]. The percentage of 5-hmC was decreased in
childhood refractory cytopenia as well as TET2 expres-
sion. This decreased expression was not associated with
the presence of mutations but was correlated with an in-
crease in microRNA-22, which may regulate the enzyme
[55]. Another study suggested that loss of %5-hmC may
be due to simple nuclear exclusion of the oxidases [56].
For breast cancer, reduced %5-hmC was assessed as a bio-
marker of tumor development [57], and TET1 decreases
were linked to poor prognosis [58]. To our knowledge, no
other team has performed a prognostic study of TET en-
zymes in CLL.
We previously demonstrated that microenvironment
stimuli influenced HDAC activity by assessing B cell recep-
tor (BCR) stimulation using anti-IgM antibodies [14]. Here,
we observed the effects of BMSC on TET1, TET3, and
IDH2 mRNA expression without the global modification
Fig. 5 Prognosis significance of 5-hydroxymethylcystosine levels. Normalized %5-hmC was measured by ELISA in B cells from a 15 ZAP70− and
15 ZAP70+ patients or b 14 LPL− and 16 LPL+ patients or c 17 CD38− and 13 CD38+ patients. Median percentages are shown in red. Statistical
differences were assessed using the Mann–Whitney non-parametric test. d Kaplan–Meier curves for TFS are shown for 15 patients with high (red) and
15 low (green) %5-hmC. The median value was used as the cut-off. Statistical differences between the curves were calculated using the log-rank test
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of %5-hmC. To confirm that these microenvironment
stimuli had no impact on DNA hydroxymethylation, we
performed the same analyses on CLL B cells cultured in
medium previously conditioned by BMSC or a CLL B
cell–BMSC co-culture. Indeed, it is known that cells pro-
duce a great variety of soluble factors whose secretion can
be modulated in the presence of other cells (with or with-
out contact). Moreover, CLL B cells and BMSC can secrete
extracellular vesicles, which act as a means of communica-
tion between cells following their integration [59]. Using
conditioned medium obtained after centrifugation, we
eliminated the possibility of BMSC contamination in the
gDNA extraction. As microenvironment stimuli do not
affect %5-hmC, it was not surprising that it was similar be-
tween different prognostic groups based on classical
markers (such as ZAP70, LPL, and CD38 status) because
poor disease progression in CLL is often linked to the re-
sponsiveness of leukemic cells to their microenvironment.
Moreover, %5-hmC was not correlated with clinical data,
such as TFS. We hypothesized that, despite TET and IDH
enzyme deregulation in CLL, these alterations have no im-
pact on global DNA hydroxymethylation itself. Decrease of
TET2 expression by siRNA (data not shown) did not influ-
ence the %5-hmC, suggesting that TET2 could have a
prognostic impact independently of its enzymatic activity.
However, TET enzymes may be involved in other pro-
cesses, and additional functional studies will be needed to
understand their impact on prognosis. TET1, for example,
has been identified as a fusion partner in the translocation
of the mixed lineage leukemia (MLL) gene in AML
[60, 61], and its oncogenic relevance depends more
on its capacity to bind DNA and recruit other pro-
teins than its enzymatic activity [15, 62].
Conclusions
In conclusion, we showed that genes involved in DNA
hydroxymethylation are deregulated in CLL and that
TET2 and IDH1 are significant predicators of TFS.
However, the prognostic value of TET and IDH mRNA
deregulation in CLL does not appear to be associated
with DNA hydroxymethylation. These data bring bio-
logical rationale for further investigations on TET and
IDH genes in CLL.
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